Anti-viral compounds and methods of using antiviral compounds are described. The compounds can be used in methods of reducing infection rate of a virus and in methods of treating a viral infection in a subject in need thereof. The virus can be a coronavirus, such as SARS-CoV-2.

Anti-viral compounds and methods of using antiviral compounds are described. The compounds can be used in methods of reducing infection rate of a virus and in methods of treating a viral infection in a subject in need thereof. The virus can be a coronavirus, such as SARS-CoV-2.

The present application discloses a compound of formula (I), compositions comprising said compound, and a method of using said compound as a cannabinoid receptor ligand in the treatment or prevention of diseases associated with a cannabinoid receptor, such as, CB1, CB2, 5HT1A, 5HT2A, GPR18, GPR119, TRPV1, TPRV2, PPARγ or a μ-opioid receptor.

The present application discloses a compound of formula (I), compositions comprising said compound, and a method of using said compound as a cannabinoid receptor ligand in the treatment or prevention of diseases associated with a cannabinoid receptor, such as, CB1, CB2, 5HT1A, 5HT2A, GPR18, GPR119, TRPV1, TPRV2, PPARγ or a μ-opioid receptor.

An application of a compound using intra-cyclic peroxo-bridged sesquiterpenes as a parent nucleus in metabolism-related fatty liver diseases is provided. The compound using intra-cyclic peroxo-bridged sesquiterpenes as the parent nucleus has the structure shown in Formula I, where A denotes O, —OH, OCH3, —OCH.sub.2CH.sub.3, or —OC.sub.4H.sub.5O.sub.3. The compound using intra-cyclic peroxo-bridged sesquiterpenes as the parent nucleus is configured for preparing a drug or a composition for treating metabolism-related fatty liver diseases. The present invention demonstrates that the compound using intra-cyclic peroxo-bridged sesquiterpenes as the parent nucleus can improve the function of mitochondria. in liver cells and enhance the fatty acid β-oxidation capacity thereof and can be used for the treatment of metabolic dysfunction due to mitochondrial dysfunction, as well as the resulting liver fat accumulation, inflammation, and fibrotic lesions.

This application provides a composition for preventing, alleviating and/or treating a heat illness, or cytotoxicity of cells such as vascular endothelial cells caused by load of heat stress and/or aberration associated with the production and release of a fever-inducing inflammatory cytokine(s) from blood cells caused by load of heat stress in a subject, comprising at least one substance selected from the group consisting of auraptene, tangeretin, and medium chain fatty acid as an active ingredient.

This application provides a composition for preventing, alleviating and/or treating a heat illness, or cytotoxicity of cells such as vascular endothelial cells caused by load of heat stress and/or aberration associated with the production and release of a fever-inducing inflammatory cytokine(s) from blood cells caused by load of heat stress in a subject, comprising at least one substance selected from the group consisting of auraptene, tangeretin, and medium chain fatty acid as an active ingredient.

Films (ODFs) that include botanical extract are provided, as well as methods of making and using the same.

Films (ODFs) that include botanical extract are provided, as well as methods of making and using the same.

A nano-pharmaceutical formulation, comprising zein nanoparticles, icariin (ICA) or a pharmaceutically acceptable salt thereof encapsulated within the zein nanoparticles, at least one solubilizer, wherein the at least one solubilizer comprises D-a-Tocopherol polyethylene glycol 1000 succinate (TPGS), and one or more pharmaceutical penetration enhancers is provided. Methods of enhancing libido by administering a composition as described herein is also provided.